Navigation Links
Icahn Indicates That Biogen Board Refuses To Close Polls

NEW YORK, June 3 /PRNewswire/ -- Carl Icahn announced today that Biogen is acting in its usual shareholder unfriendly way by manipulating the annual meeting of shareholders in order the prevent the votes that have been submitted from being counted. They are doing so in order to attempt to keep two of the Icahn nominees from winning seats on the Board. If the Board is successful, Richard Mulligan, a prominent scientist and physician, may be kept from legitimately being elected to the Board. This is a consistent theme of this Board. Do everything possible to keep shareholders from entering into the Board's private club to ensure that shareholders are kept in the dark about what the Board is doing, just as they were about last year's sale process. Mr. Icahn concluded that "shareholders should demand that this Board finally act in their interest instead of just attempting to relect themselves. There is absolutely no reason to adjourn the meeting for hours in order to keep the polls open. Do not let them get away with hijacking the election."

SOURCE Carl Icahn
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amylin Issues Statement in Response to Carl Icahn
2. Icahn Asks Amylin to Allow Discussions With Eastbourne
3. Icahn Responds to Cornelius
4. Icahn Confirms Intention to Nominate Three Directors at Biogen
5. Baseline Research Indicates High Interest in Centocor-Ortho Biotechs SIMPONI(R)
6. New study indicates smallpox vaccination effective for decades
7. New study indicates smallpox vaccination effective for decades
8. Data Presented at ASH Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias
9. Vaccines are Likely to Cause Insulin Dependent Diabetes in Over 2% of Children With a Strong Family History of Insulin Dependent Diabetes, New Data Indicates
10. New Independent Research Study Indicates That Cylexs ImmuKnow Test May Identify Kidney Transplant Patients at Risk for Early Acute Rejection
11. Abbott & BioGenex Extend the Technology Co-development and Distribution Agreement for Marketing the Xmatrx(R) Advanced Staining Platform for the Automation of FISH, IHC and ISH Molecular Diagnostic Assays
Post Your Comments:
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... While ... machines such as the Cary 5000 and the 6000i models are higher end machines ... is the height of the spectrophotometer’s light beam from the bottom of the cuvette ...
(Date:6/23/2016)... ... 23, 2016 , ... UAS LifeSciences, one of the leading ... UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing high ... its list of well-respected retailers. This list includes such fine stores as Whole ...
(Date:6/23/2016)... , June 23, 2016 A person commits a ... crime scene to track the criminal down. An ... Food and Drug Administration (FDA) uses DNA evidence to track ... Sound far-fetched? It,s not. The FDA has increasingly ... support investigations of foodborne illnesses. Put as simply as possible, ...
(Date:6/23/2016)... 23, 2016  The Prostate Cancer Foundation (PCF) is pleased to ... faster cures for prostate cancer. Members of the Class of 2016 were selected ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:6/2/2016)... 2016   The Weather Company , an IBM Business ... industry-first capability in which consumers will be able to interact ... questions via voice or text and receive relevant information about ... Marketers have long sought an advertising solution that can ... personal, relevant and valuable; and can scale across millions of ...
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of the medical ... premium product recently added to the range of products distributed by Ampronix. ... ... ... Ampronix News ...
(Date:5/12/2016)... , May 12, 2016 , ... published the overview results from the Q1 wave of ... recent wave was consumers, receptivity to a program where ... with a health insurance company. "We were ... share," says Michael LaColla , CEO of Troubadour ...
Breaking Biology News(10 mins):